Introduction to Investigational New Drug (IND) Applications (3/14) REdI 2017

  Рет қаралды 20,804

U.S. Food and Drug Administration

U.S. Food and Drug Administration

Күн бұрын

Пікірлер
FDA Communication During Drug Development (4/14) REdI 2017
40:24
U.S. Food and Drug Administration
Рет қаралды 4,1 М.
Chemistry, Manufacturing Controls (CMC) in an Investigational New Drug (IND) (7/14) REdI 2017
1:20:20
Quilt Challenge, No Skills, Just Luck#Funnyfamily #Partygames #Funny
00:32
Family Games Media
Рет қаралды 25 МЛН
Кто круче, как думаешь?
00:44
МЯТНАЯ ФАНТА
Рет қаралды 6 МЛН
Overview of Non-clinical Assessment in Drug Development (8/14) REdI 2017
54:28
U.S. Food and Drug Administration
Рет қаралды 16 М.
Chemistry, Manufacturing, and Controls (CMC) for an IND (7of14) REdI 2018
1:19:35
U.S. Food and Drug Administration
Рет қаралды 28 М.
Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018
33:18
Nonclinical Safety Assessment for Small Molecules and Biologic Drug Development (6of14) REdI 2018
44:31
Post-approval Considerations for Changes to Manufacturing Process and Facilities - REdI 2020
28:11
77th Cellular, Tissue, and Gene Therapies Advisory Committee
5:59:50
U.S. Food and Drug Administration
Рет қаралды 3,9 М.
Designing First-In-Human Trials for Small Molecules and Biologics
37:34
U.S. Food and Drug Administration
Рет қаралды 11 М.
CMC Considerations for CAR T Cell Product Development
29:42
U.S. Food and Drug Administration
Рет қаралды 12 М.
FDA Drug Manufacturing Inspections - REdI 2020
52:33
U.S. Food and Drug Administration
Рет қаралды 9 М.
Clinical Pharmacology Considerations for Radiolabeled Mass Balance Studies
1:00:00
U.S. Food and Drug Administration
Рет қаралды 568